C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in C4 Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +4 vs. Q4 2024
- Shares held
- 64.1M
- −74.9K (−0.1%) vs. Q4 2024
- Total value
- $102.6M
- −$128.5M (−55.6%) vs. Q4 2024
- New holders
- 27
- 39 more added
- Sold out
- 23
- 29 more reduced
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 900,000 | $1.44M | 0.08% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $1.78M | 0.26% | 00.0% | Unchanged |
| State Street Corp | 1,224,418 | $1.96M | 0.00% | +1,400+0.1% | Added |
| ArrowMark Colorado Holdings LLC | 1,286,712 | $2.06M | 0.03% | −47,389−3.6% | Reduced |
| Geode Capital Management, LLC | 1,430,288 | $2.29M | 0.00% | +49,202+3.6% | Added |
| Adage Capital Partners GP, L.L.C. | 1,550,000 | $2.48M | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,990,824 | $3.19M | 0.00% | +313,182+18.7% | Added |
| Samlyn Capital, LLC | 3,015,139 | $4.82M | 0.08% | −4,319−0.1% | Reduced |
| Vanguard Group Inc | 3,370,880 | $5.39M | 0.00% | +24,907+0.7% | Added |
| Morgan Stanley | 4,045,329 | $6.47M | 0.00% | +205,860+5.4% | Added |
| BlackRock, Inc. | 5,284,413 | $8.46M | 0.00% | −274,438−4.9% | Reduced |
| Wasatch Advisors Inc | 6,724,409 | $10.8M | 0.06% | +651,808+10.7% | Added |
| OrbiMed Advisors LLC | 6,830,300 | $10.9M | 0.26% | +2,452,400+56.0% | Added |
| Soleus Capital Management, L.P. | 6,978,942 | $11.2M | 0.88% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 7,098,133 | $11.4M | 4.07% | +245,389+3.6% | Added |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −4,878,000−100.0% | Sold out |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −283,705−100.0% | Sold out |
| Sio Capital Management, LLC | 0 | $0 | 0.00% | −155,000−100.0% | Sold out |
| M&T Bank Corp | 0 | $0 | 0.00% | −132,715−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −109,825−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −69,628−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −59,654−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −51,000−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −42,533−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −40,819−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −36,167−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −34,242−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −32,883−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −28,616−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −25,555−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −23,176−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −22,693−100.0% | Sold out |
| Kazazian Asset Management, LLC | 0 | $0 | 0.00% | −14,250−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −11,333−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −6,871−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −3,310−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −3,033−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |
| Caxton Associates LP | – | – | – | – | Not filed |